Generic Name and Formulations:
Minoxidil 2.5 mg, 10 mg; scored tabs.
Various generic manufacturers
Indications for Minoxidil:
Refractory hypertension, usually with a diuretic and β-blocker (see literature).
Initially 5 mg once daily; may increase at 3-day intervals to 10 mg/day, then 20 mg/day, then 40 mg/day (monitor closely if titrated faster). Usual range 10–40 mg/day; max 100 mg/day. If drop in diastolic pressure >30 mmHg, give in 2 divided doses.
Initially 0.2 mg/kg once daily; may increase at 3-day intervals by 50–100%. Usual range 0.25–1 mg/kg per day; max 50 mg/day.
Supervise closely. Do not use in patients with history of recurrent pericarditis, or history of recurrent or chronic pericardial effusion. Malignant hypertension. Angina. Post MI. Heart failure. Renal dysfunction. Monitor fluid and electrolyte balance, body weight, and for pericardial effusion. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid guanethidine (hospitalize until stable if used).
Pericardial effusion or tamponade, pericarditis, salt/fluid retention, cardiac failure, tachycardia, angina, hypertrichosis, rash, GI upset, ECG changes; rare: Stevens-Johnson syndrome, thromobocytopenia, leukopenia.
Formerly known under the brand names Loniten, Minodyl.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|